NRX Pharmaceuticals (NRXP) Gains from Investment Securities (2021 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Gains from Investment Securities of -$3.5 million for Q1 2026, down 22.17% year-over-year from -$4.5 million in Q1 2025, and down 1.64% quarter-over-quarter from -$3.5 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Gains from Investment Securities (2021 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Gains from Investment Securities for 6 consecutive years, with -$3.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 22.17% year-over-year to -$3.5 million; the TTM figure through Mar 2026 stood at $6.5 million (up 619.31% YoY), while the FY2025 annual figure was $5.0 million, up 201.75% from the prior year.
- Gains from Investment Securities declined to -$3.5 million in Q1 2026 per NRXP's latest filing, from -$3.5 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $8.5 million in Q2 2025 and bottomed at -$3.5 million in Q1 2026.
- Historically, Gains from Investment Securities has averaged $122529.4 across 5 years, with a median of -$19000.0 in 2022.
- On a YoY basis, Gains from Investment Securities climbed as much as 47322.22% in 2025 and fell as far as 32277.78% in 2025.
- NRX Pharmaceuticals' Gains from Investment Securities stood at -$19000.0 in 2022, then surged by 136.84% to $7000.0 in 2023, then soared by 26057.14% to $1.8 million in 2024, then tumbled by 290.11% to -$3.5 million in 2025, then slipped by 1.64% to -$3.5 million in 2026.
- Business Quant data shows NRXP's Gains from Investment Securities at -$3.5 million in Q1 2026, -$3.5 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.54 Mn |
| Mar 31, 2026 | -3.54 Mn |
| Dec 31, 2025 | -3.48 Mn |
| Dec 31, 2025 | -3.48 Mn |
| Sep 30, 2025 | 5.00 Mn |
| Sep 30, 2025 | 5.00 Mn |
| Jun 30, 2025 | 8.50 Mn |
| Jun 30, 2025 | 8.50 Mn |
| Mar 31, 2025 | -2.90 Mn |
| Mar 31, 2025 | -2.90 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Sep 30, 2024 | -165,000.00 |
| Sep 30, 2024 | -165,000.00 |
| Jun 30, 2024 | -18,000.00 |
| Jun 30, 2024 | -18,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Dec 31, 2023 | 7,000.00 |